Mirikizumab (Omvoh) improved outcomes in patients with moderately-to-severely active Crohn's disease with previous failure to ...

Researchers report results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors ...

Discover how nicotinamide riboside reduces airway inflammation in COPD patients by lowering IL-8 levels and enhancing ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Reaches Alignment with FDA Regarding Phase 3 Trial Plan On November 25, 2024, Imunon, Inc. (NASDAQ:IMNN) announced it had reached alignment with ...

FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment ...

IMUNON (IMNN) announced the outcome of its recent End-of-Phase 2 in-person meeting with the U.S. Food and Drug Administration, FDA, supporting ...

Mural Oncology (NASDAQ:MURA – Get Free Report) is one of 1,048 public companies in the “Pharmaceutical preparations” industry ...

The US Food and Drug Administration has approved bimekizumab, a humanized interleukin (IL)-17A and IL-17F antagonist, for the ...

The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...

The researchers utilized a Fra-2 transgenic mouse model that encompasses many of the features of systemic sclerosis in humans, including spontaneous systemic inflammation and fibrosis in the lungs, ...

Entyvio is given as an IV infusion at a clinic every eight weeks. Stelara, also known as ustekinumab, is a monoclonal antibody that targets specific proteins called interleukin-12 (IL-12) and ...

4G bands 1, 2, 3, 4, 5, 7, 8, 12, 13, 14, 17, 18, 19, 20, 25, 26, 28, 29, 30, 32, 34, 38, 39, 40, 41, 42, 46, 48, 66, 71 - A2176 1, 2, 3, 4, 5, 7, 8, 12, 13, 17, 18 ...